-
Je něco špatně v tomto záznamu ?
The source of MHC class I presented peptides and its implications
S. Apcher, R. Prado Martins, R. Fåhraeus,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, přehledy
- MeSH
- alternativní sestřih MeSH
- antigeny genetika metabolismus MeSH
- histokompatibilita - antigeny třídy I metabolismus MeSH
- lidé MeSH
- nepřímá aktivace MeSH
- peptidy genetika metabolismus MeSH
- prezentace antigenu MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
The source of peptides that enter the major histocompatibility class I (MHCI) pathway has been intensively debated over the last two decades. The initial assumption that peptides are derived from degradation of full length proteins was challenged by a model in which alternative translation products are a source of peptides. This model has been tested and supported by scientific data. We now need new hypotheses on the physiological implications of different sources of peptides for the MHCI pathway. The aim of this overview is to give an up-to-date account of the source of antigenic peptide material for the MHCI pathway and to incorporate the more recent observations of alternative mRNA translation products into existing models of the direct and cross-presentation pathways.
Department of Medical Biosciences Umeå University SE 90185 Umeå Sweden
RECAMO Masaryk Memorial Cancer Institute Zluty kopec 7 656 53 Brno Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18017293
- 003
- CZ-PrNML
- 005
- 20180523094501.0
- 007
- ta
- 008
- 180515s2016 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.coi.2016.04.002 $2 doi
- 035 __
- $a (PubMed)27105144
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Apcher, Sébastien $u Institut Gustave Roussy, Université Paris Sud, Unité 1015 département d'immunologie, 114, rue Edouard Vaillant, 94805 Villejuif, France.
- 245 14
- $a The source of MHC class I presented peptides and its implications / $c S. Apcher, R. Prado Martins, R. Fåhraeus,
- 520 9_
- $a The source of peptides that enter the major histocompatibility class I (MHCI) pathway has been intensively debated over the last two decades. The initial assumption that peptides are derived from degradation of full length proteins was challenged by a model in which alternative translation products are a source of peptides. This model has been tested and supported by scientific data. We now need new hypotheses on the physiological implications of different sources of peptides for the MHCI pathway. The aim of this overview is to give an up-to-date account of the source of antigenic peptide material for the MHCI pathway and to incorporate the more recent observations of alternative mRNA translation products into existing models of the direct and cross-presentation pathways.
- 650 _2
- $a alternativní sestřih $7 D017398
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a prezentace antigenu $7 D017951
- 650 _2
- $a antigeny $x genetika $x metabolismus $7 D000941
- 650 _2
- $a nepřímá aktivace $7 D045142
- 650 _2
- $a histokompatibilita - antigeny třídy I $x metabolismus $7 D015395
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a peptidy $x genetika $x metabolismus $7 D010455
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Prado Martins, Rodrigo $u Equipe Labellisée la Ligue Contre le Cancer, Inserm UMR1162, Université Paris 7, Institut de Génétique Moléculaire, 27 rue Juliette Dodu, 75010 Paris, France.
- 700 1_
- $a Fåhraeus, Robin $u Equipe Labellisée la Ligue Contre le Cancer, Inserm UMR1162, Université Paris 7, Institut de Génétique Moléculaire, 27 rue Juliette Dodu, 75010 Paris, France; RECAMO, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic; Department of Medical Biosciences, Umeå University, SE-90185 Umeå, Sweden. Electronic address: robin.fahraeus@inserm.fr.
- 773 0_
- $w MED00001285 $t Current opinion in immunology $x 1879-0372 $g Roč. 40, č. - (2016), s. 117-22
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27105144 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180523094645 $b ABA008
- 999 __
- $a ok $b bmc $g 1300917 $s 1014133
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 40 $c - $d 117-22 $e 20160419 $i 1879-0372 $m Current opinion in immunology $n Curr Opin Immunol $x MED00001285
- LZP __
- $a Pubmed-20180515
